Filing Summary
Passage Bio, Inc. filed a Form 8-K dated May 27, 2021, reporting results of its 2021 Annual Meeting of Stockholders. The filing does not report financial results for a specific operating period.
Meeting Results
- Stockholders elected three Class I directors for terms expiring at the 2024 Annual Meeting: Bruce Goldsmith, Ph.D.; Derrell Porter, M.D.; and Tadataka Yamada, M.D.
- Votes for, withheld, and broker non-votes were 40,579,003, 2,015,796, and 3,027,672, respectively, for Bruce Goldsmith.
- Votes for, withheld, and broker non-votes were 42,135,625, 459,174, and 3,027,672, respectively, for Derrell Porter.
- Votes for, withheld, and broker non-votes were 40,192,611, 2,402,188, and 3,027,672, respectively, for Tadataka Yamada.
- Stockholders ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, with 45,595,941 votes for, 14,733 against, and 11,797 abstaining.
Financial Metrics and Material Changes
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating metrics. It does not disclose material changes versus a prior comparable period.
Outlook, Risks, and Unusual Items
No new guidance, management outlook, risk updates, contingencies, or unusual financial items are disclosed. The principal governance items were director elections and auditor ratification.
Investor Verification Items
- Verify the elected directors’ roles, committee assignments, and independence status in subsequent filings.
- Review the company’s fiscal 2021 periodic reports for financial results, cash runway, financing needs, and clinical-development updates.
- Confirm KPMG LLP’s continued appointment and review any subsequent auditor-related disclosures.